How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,040 results for

Antithyroid Drug

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Association of HLA-B∗38:02 with Antithyroid Drug-Induced Agranulocytosis in Kinh Vietnamese Patients Full Text available with Trip Pro

Association of HLA-B∗38:02 with Antithyroid Drug-Induced Agranulocytosis in Kinh Vietnamese Patients HLA-B∗38:02 has been shown to be associated with antithyroid drug-induced agranulocytosis in Asian patients.HLA-B∗38:02 was analyzed by sequence-based typing in 21 patients who developed antithyroid drug-induced agranulocytosis and in 81 controls.Frequency of HLA-B∗38:02 was 52.4% in agranulocytosis patients compared to 3.7% in controls (OR = 28.6, 95% CI = 6.8-120.2).HLA-B∗38:02 (...) is a significant risk factor for agranulocytosis in Kinh Vietnamese patients treated with antithyroid drug.

2018 International journal of endocrinology

22. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves’ ophthalmopathy – a 1-year follow-up: study protocol for a randomized controlled trial Full Text available with Trip Pro

manifestation, has been demonstrated. Graves' ophthalmopathy (GO) is typically characterized by an inflammation and expansion of the extraocular muscles and an increase in retroorbital fat. There are currently three forms of therapies offered for hyperthyroidism caused by Graves' disease: antithyroid drugs (ATD) (thionamides), radioiodine ablation (RAI) and thyroidectomy (Tx). To date, there is no clear recommendation on the treatment of Graves' disease and GO, mainly due to the individuality of the disease (...) Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves’ ophthalmopathy – a 1-year follow-up: study protocol for a randomized controlled trial Graves' disease (GD) is characterized by thyrotoxicosis and goiter and arises through circulating autoantibodies that bind to, and stimulate, the thyroid hormone receptor (TSHR). A temporal relation between the onset of hyperthyroidism and the onset of ophthalmopathy, a common extrathyroidal

2018 Trials

23. Serum TSH Level as Predictor of Graves' Disease Recurrence Following Antithyroid Drug Withdrawal

Serum TSH Level as Predictor of Graves' Disease Recurrence Following Antithyroid Drug Withdrawal Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external (...) . No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data

2020 PROSPERO

24. Psychosis and antithyroid drug therapy. Full Text available with Trip Pro

Psychosis and antithyroid drug therapy. 4184813 1969 10 05 2013 11 21 0007-1447 3 5670 1969 Sep 06 British medical journal Br Med J Psychosis and antithyroid drug therapy. 596-7 Hedley A J AJ Bewsher P D PD eng Journal Article England Br Med J 0372673 0007-1447 0 Antithyroid Agents 0 Imidazoles 8KQ660G60G Carbimazole AIM IM Adult Antithyroid Agents adverse effects Carbimazole adverse effects Female Humans Imidazoles adverse effects Psychoses, Substance-Induced etiology 1969 9 6 1969 9 6 0 1

1969 British medical journal

25. Results of Treatment of Thyrotoxicosis following Relapse after Antithyroid Drug Therapy Full Text available with Trip Pro

Results of Treatment of Thyrotoxicosis following Relapse after Antithyroid Drug Therapy One hundred and thirty patients who relapsed after a full course of treatment with antithyroid drugs have been reviewed. Of 22 patients receiving a second course of antithyroid drugs, 17 (77%) relapsed. In contrast, only 2 out of 44 patients treated by surgery relapsed and seven became hypothyroid. Nevertheless, local complications, in particular parathyroid insufficiency, were especially common

1969 British medical journal

26. Prediction of response to medical therapy by serum soluble (pro)renin receptor levels in Graves' disease. Full Text available with Trip Pro

Prediction of response to medical therapy by serum soluble (pro)renin receptor levels in Graves' disease. Antithyroid drugs are generally selected as the first-line treatment for Graves' Disease (GD); however, the existence of patients showing resistance or severe side effects to these drugs is an important issue to be solved. The (pro)renin receptor [(P)RR] is a multi-functional protein that activates the tissue renin-angiotensin system and is an essential constituent of vacuolar H+-ATPase (...) , necessary for the autophagy-lysosome pathway. (P)RR is cleaved to soluble (s)(P)RR, which reflects the status of (P)RR expression. In this retrospective study, we aimed to investigate whether serum s(P)RR concentration can be used as a biomarker to predict the outcome of antithyroid drug treatment in GD patients. Serum s(P)RR levels were measured in 54 untreated GD patients and 47 control participants. Effects of medical treatment with antithyroid drugs on these levels were investigated in GD patients

2018 PLoS ONE

27. Birth defects after use of antithyroid drugs in early pregnancy: a Swedish nationwide study. Full Text available with Trip Pro

Birth defects after use of antithyroid drugs in early pregnancy: a Swedish nationwide study. Antithyroid drugs (ATDs) may have teratogenic effects, but more evidence is needed on the risk and types of birth defects after the use of methimazole (MMI) and propylthiouracil (PTU). This study aimed to evaluate the association between the use of ATDs in early pregnancy and birth defects.Swedish nationwide register-based cohort study.The study included 684 340 children live-born in Sweden from 2006

2017 European Journal of Endocrinology

28. Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves’ disease Full Text available with Trip Pro

Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves’ disease Graves' disease (GD) accounts for a large proportion of pediatric hyperthyroidism, and the first-line treatment is antithyroid drug (ATD) therapy. Methimazole (MMI) is effective in most patients but is associated with significant adverse events (AEs). We reviewed the medical records of GD patients (n = 56) with onset age of <15 yr and investigated the relationship between MMI dose

2017 Clinical Pediatric Endocrinology

29. Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management Full Text available with Trip Pro

Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management Agranulocytosis is a rare but serious complication of antithyroid drug therapy, and an up-to-date understanding of this topic is important. Both direct toxicity and immune-mediated responses have been described as possible mechanisms. Some major susceptibility loci have recently been identified, which may lead the diagnosis of agranulocytosis into a genomic era. Onset is acute and patients present (...) with symptoms and signs of infection together with high fever. Clinical suspicion is pivotal and should prompt blood sampling. An absolute neutrophil count of <500/μl in the presence of antithyroid drugs establishes the diagnosis. The causative drug should immediately be stopped to prevent further damage. Treatment includes broad-spectrum antibiotics and granulocyte-colony stimulation factor in selected patients. Later, patients will need definitive treatment for hyperthyroidism, usually with radioactive

2017 Drugs in R&D

30. Association of HLA-B and HLA-DRB1 polymorphisms with antithyroid drug-induced agranulocytosis in a Han population from northern China Full Text available with Trip Pro

Association of HLA-B and HLA-DRB1 polymorphisms with antithyroid drug-induced agranulocytosis in a Han population from northern China Antithyroid drug (ATD)-induced agranulocytosis is associated with human leukocyte antigen (HLA) and nearby genes in Southeast Asian and European populations. The susceptibility of the Han population from northern China to ATD-induced agranulocytosis has not been reported. We evaluated the associations of genetic variants at the HLA-B and HLA-DRB1 loci and 32

2017 Scientific reports

31. Predictive Value of Gene Polymorphisms on Recurrence after the Withdrawal of Antithyroid Drugs in Patients with Graves’ Disease Full Text available with Trip Pro

Predictive Value of Gene Polymorphisms on Recurrence after the Withdrawal of Antithyroid Drugs in Patients with Graves’ Disease Graves' disease (GD) is one of the most common endocrine diseases. Antithyroid drugs (ATDs) treatment is frequently used as the first-choice therapy for GD patients in most countries due to the superiority in safety and tolerance. However, GD patients treated with ATD have a relatively high recurrence rate after drug withdrawal, which is a main limitation for ATD

2017 Frontiers in endocrinology

32. Risk factors for the relapse of Graves' disease treated with antithyroid drugs: a systematic review and meta-analysis

Risk factors for the relapse of Graves' disease treated with antithyroid drugs: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated (...) . No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data

2019 PROSPERO

33. MANAGEMENT OF ENDOCRINE DISEASE: Arguments for the prolonged use of antithyroid drugs in children with Graves' disease. Full Text available with Trip Pro

MANAGEMENT OF ENDOCRINE DISEASE: Arguments for the prolonged use of antithyroid drugs in children with Graves' disease. Graves' disease is an autoimmune disorder. It is the leading cause of hyperthyroidism, but is rare in children. Patients are initially managed with antithyroid drugs (ATDs), such as methimazole/carbimazole. A major disadvantage of treatment with ATD is the high risk of relapse, exceeding 70% of children treated for duration of 2 years, and the potential major side effects (...) of the drug reported in exceptional cases. The major advantage of ATD treatment is that normal homeostasis of the hypothalamus-pituitary-thyroid axis may be restored, with periods of drug treatment followed by freedom from medical intervention achieved in approximately 40-50% of cases after prolonged treatment with ATD, for several years, in recent studies. Alternative ablative treatments such as radioactive iodine and, less frequently and mostly in cases of very high volume goiters or in children under

2017 European Journal of Endocrinology

34. Genetic variants associated with antithyroid drug-induced agranulocytosis

Genetic variants associated with antithyroid drug-induced agranulocytosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect (...) articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text

2018 PROSPERO

35. Antithyroid Drug

with Methimazole Hepatitis Occurs with both Methimazole and Propylthiouracil (PTU) Methimazole associated hepatitis : 3.17 per 1000 person-years : 0.32 per 1000 person-years Propylthiouracil (PTU) is associated with severe liver injury Adults: 1 in 10,000 Children: 1 in 2,000 -like syndrome Rash or Switch from PTU to Methimazole if severe or Congenital abnormalities possible with Methimazole VI. Monitoring Repeat examination every 3 months before starting therapy Lab Testing while on antithyroid medications (...) SnomedCT 5067008 , 418416001 English Antagonists, Thyroid , Antithyroid Drugs , Drugs, Antithyroid , Thyroid Antagonists , thyroid inhibitor , Agents, Antithyroid , Antithyroid Agents , THYROID ANTAG , ANTITHYROID AGENTS , anti-thyroid agents , anti-thyroid agents (medication) , thyroid antagonists , [HS852] ANTITHYROID AGENTS , antithyroid drug , inhibitors thyroid , antithyroid agents , antithyroid preparations , antithyroid drugs , Thyroid Antagonist , ANTITHYROID PREPARATIONS , Thyroid antagonists

2018 FP Notebook

36. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study Full Text available with Trip Pro

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study Immune checkpoint inhibitors, including anti-programmed cell death-1 (PD-1) antibodies, have become promising treatments for a variety of advanced malignancies. However, these medicines can cause immune-related adverse events (irAEs), including endocrinopathies.This study examined the incidence of endocrine irAEs induced by nivolumab.Sixty-six patients treated with nivolumab (...) at Nagoya University Hospital were prospectively evaluated for pituitary hormones, thyroid function, antithyroid antibodies (Abs), and glucose levels every 6 weeks after the initiation of nivolumab for 24 weeks.Four out of 66 patients developed destructive thyroiditis, and three patients developed hypothyroidism requiring levothyroxine replacement. The prevalence of positive anti-thyroglobulin Abs (TgAbs) and/or anti-thyroid peroxidase Abs (TPOAbs) at baseline was significantly higher in the group

2018 Journal of the Endocrine Society

37. Antithyroid Drug Side Effects in the Population and in Pregnancy. Full Text available with Trip Pro

Antithyroid Drug Side Effects in the Population and in Pregnancy. Methimazole (MMI) and propylthiouracil (PTU) are both associated with birth defects and may also rarely be associated with agranulocytosis and liver failure. The frequency of these side effects when antithyroid drugs (ATDs) are used in the population in general or in pregnancy remains to be elucidated.All individuals registered as the parent of a live-born child in Denmark, 1973–2008, were identified (n = 2 299 952) and studied

2016 Journal of Clinical Endocrinology and Metabolism

38. Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: A retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. (Abstract)

Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: A retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Antithyroid drug (ATD)-induced agranulocytosis is a rare but life-threatening disease. Clinical features of ATD-induced agranulocytosis and outcomes remain incompletely understood.Patients with clinically diagnosed ATD-induced agranulocytosis were (...) retrospectively studied, involving 9690 patients who were referred for radioiodine treatment during a 15-year period (2000-2015) in China. There were 114 cases of agranulocytosis attributable to ATD included, and their clinical characteristics and therapy outcomes were analyzed.The female-to-male ratio of ATD-induced agranulocytosis was 10.4:1. The mean age (±standard deviation) of the patients with ATD-induced agranulocytosis was 41.7 ± 12.3 years. The methimazole and propylthiouracil doses given

2016 Thyroid

39. Antithyroid drug-associated MPO-ANCA-positive tubulointerstitial nephritis in a type 2 diabetes patient: a case report Full Text available with Trip Pro

Antithyroid drug-associated MPO-ANCA-positive tubulointerstitial nephritis in a type 2 diabetes patient: a case report A 54-year-old man diagnosed with type 2 diabetes and hyperthyroidism was prescribed propylthiouracil (PTU) after the patient developed hepatic dysfunction on thiamazole. At 50 mg/day of PTU, he was stable with thyroid-stimulating hormone receptor and thyrotropic antibody titers remaining stable. After four years of taking PTU, he was referred to the Department of Nephrology due

2016 CEN Case Reports

40. The effect of prior antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation Full Text available with Trip Pro

The effect of prior antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation Antithyroid drugs (ATDs) have been shown to attenuate the effectiveness of radioiodine (radioiodine ablation, RIA) therapy in Graves' disease. We undertook a study to look at the impact of iodine uptakes on the outcome of (131)I therapy. To determine the effect of prior ATD use on the duration of time to achieve cure in patients with high vs intermediate uptake Graves (...) of low free thyroxin and rising TSH levels. When a standard dose of 15 mCi (131)I was administered, a cure rate of 93% was achieved. The median duration of time to cure (TC) was 129 days. Surprisingly, a direct proportional linear relationship (R(2)=0.92) was established between time to cure and radioiodine uptake (TC> 3 0%=172days, TC10 - 3 0%=105 days, P<0.001). Patients who used ATD medications took a proportionately longer duration to achieve remission (TCNO ATD=102days, TCATD=253days, P<0.001

2016 Endocrine connections

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>